ScienceDirect, 06/2026
The Challenge of Cesarean Scar Defects
Infertility has emerged as a major global health challenge, affecting approximately 10–25% of reproductive-aged couples worldwide. Among women seeking infertility treatment, roughly 6% suffer from uterine dysfunction.
The rapid escalation of global Cesarean section (C-section) rates—surging from 16.0 million in 2000 to 29.7 million in 2015—presents severe obstetric implications. The incidence of Cesarean scar defects (CSDs) is estimated to range between 19–86%, frequently leading to gynecological complications such as menstrual disorders, intrauterine adhesions, and irreversible secondary infertility.
Current therapeutic approaches, including hormone therapy and cryotherapy, fail to fully restore comprehensive uterine function. Furthermore, systemic drug administration not only lacks local therapeutic efficacy but also poses cardiovascular risks due to exogenous estrogen exposure. Meanwhile, conventional intravenous mesenchymal stem cell (MSC) transplantation results in a loss of over 60% of cells trapped in the lungs, and direct transplantation onto injured tissues remains severely limited by poor cell survival within the harsh lesion microenvironment.
The Solution: “MN-MSC” Hybrid Micro/Nano Engineering Platform
To address these limitations, researchers have successfully engineered an advanced local delivery system: the hybrid porous microneedle-hydrogel (MN-MSC) patch.
- Structural Composition: The patch consists of a conical porous microneedle (MN) array fabricated from a Gelatin Methacryloyl (GelMA) matrix, featuring a base diameter of 280 μm and a height of 800 μm. This array is overlaid with a hydrogel layer embedded with viable umbilical cord mesenchymal stem cells (UCMSCs).
- Paracrine Release Mechanism: The hydrogel layer serves as a protective microenvironment, sustaining UCMSC viability for at least 28 days without requiring direct cellular infiltration into the uterine wound. From this reservoir, bioactive extracellular vesicles (EVs) and paracrine factors are continuously, sustainably, and locally delivered through the porous microneedles directly into the target tissue.
- Mechanical Functionality: The hydrogel backing simultaneously acts as a physical barrier, effectively preventing post-surgical adhesions between the uterine wound and adjacent abdominal tissues.
Experimental Outcomes
Evaluated in a rat model with severe uterine injury, the MN-MSC patch demonstrated breakthrough therapeutic outcomes verified through integrated proteomics, bioinformatics, and functional validation:
- Significantly suppressed uterine tissue fibrosis.
- Promoted robust angiogenesis, myometrial regeneration, and endometrial reconstruction.
- Restored Fertility: The pregnancy rate and live birth outcomes in the MN-MSC patch-treated group were remarkably improved, returning to levels comparable to those of the healthy control group.
Future Perspectives
This research introduces a highly promising strategy for scarless tissue regeneration. Beyond its applications in obstetrics and gynecology, this micro/nano-engineered platform for the sustained, localized delivery of living cell secretomes holds broad translational potential in clinical regenerative medicine, particularly for chronic cutaneous wound healing and myocardial infarction repair.
Source: ScienceDirect
Link: https://www.sciencedirect.com/science/article/abs/pii/S1748013226001040
